1. Viral contamination in biologic manufacture and implications for emerging therapies;Barone;Nat Biotechnol,2020
2. Adventitious agents in viral vaccines: lessons learned from 4 case studies;Petricciani;Biologicals,2014
3. Anonymous. ICH Q5A (R1) Quality of biotechnological products: viral safety evaluation biotechnology products derived from cell lines human or animal origin. European Medicines Agency 2018. https://www.ema.europa.eu/en/ich-q5a-r1-quality-biotechnological-products-viral-safety-evaluation-biotechnology-products-derived (accessed January 26, 2022).
4. EMA. ICH Guideline Q5A(R2) on viral safety evaluation of biotechnology products derived from cell lines human or animal origin - Scientific guideline. European Medicines Agency 2018. https://www.ema.europa.eu/en/ich-guideline-q5ar2-viral-safety-evaluation-biotechnology-products-derived-cell-lines-human-animal (accessed May 3, 2023).
5. Research C for BE and. Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications. US Food and Drug Administration 2019. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/characterization-and-qualification-cell-substrates-and-other-biological-materials-used-production (accessed January 26, 2022).